Travere Therapeutics Reports Q2 2025 Earnings with Strong Sales Growth

Travere Therapeutics (TVTX) reported Q2 2025 earnings with strong net product sales, driven by increased demand for FILSPARI and THIOLA. The company saw an 82% year-over-year revenue growth, with total revenue reaching $114.4 million. The results highlight improved prescriber engagement and a one-time milestone payment from CSL Vifor.

By Motley Fool Transcribing · Motley Fool · May 4, 2026, 19:01 UTC

Travere Therapeutics Reports Q2 2025 Earnings with Strong Sales Growth

Tickers: $TVTX

Topics: FILSPARI net product sales pharmaceutical industry R&D expenses revenue growth

Read the full article at Motley Fool

More World news

IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC
Nvidia CEO Jensen Huang Resigns Amid Investigation and Personal Allegations Motley Fool · November 12, 2026, 17:20 UTC
Argus Research Upgrades Republic Services to Buy Seeking Alpha · November 12, 2026, 17:16 UTC
Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns Motley Fool · November 12, 2026, 17:13 UTC
United Airlines Restricts AI Agent Access to Booking Systems Due to Cybersecurity and Regulatory Concerns TechCrunch · November 12, 2026, 17:17 UTC
Global Payments Shares Drop 12% Following Reports Private Equity Firms Abandoned Takeover Bid Seeking Alpha · November 12, 2026, 17:14 UTC
Nvidia Appoints Colette Kress as Interim CEO Following Jensen Huang's Resignation CNBC · November 12, 2026, 16:59 UTC
Brookfield Corporation Reports Strong Third Quarter Earnings Growth and Increased Share Buybacks Motley Fool · November 12, 2026, 17:08 UTC
Franco-Nevada Reports Q3 2026 Revenue Growth Driven by Higher Gold and Oil Prices Motley Fool · November 12, 2026, 17:10 UTC